Ernexa Shares Dip 1.42% as ERNA‑101 Advances Toward First‑Human Ovarian Cancer Trial
Ernexa Therapeutics’ stock dips as ERNA‑101 enters first‑in‑human ovarian cancer trials, highlighting new immunotherapy tech and FDA talks.
- ERNEXA THERAPEUTICS INC
- United States
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
3 minutes to read